R1216- Randomized Phase II/III Trial Of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, Or Cisplatin-Atezolizumab In Pathologic High-Risk Squamous Cell Cancer Of The Head And Neck
Posted Date: Jan 18, 2021
- Investigator: Sara Medek
- Specialties: Cancer, Head and Neck Cancer, Oncology, Radiation Oncology
- Type of Study: Drug
The main purpose of this study is to determine if the combination of docetaxel-cetuximab and IMRT is superior in terms of overall survival (OS) compared to standard cisplatin and IMRT in the adjuvant treatment of pathologic high risk, HPV-negative HNSCC.
Criteria:
To Be Eligible: Must Have Diagnosis Of Stage Iii Or Iv Head And Neck Squamous Cell Carcinoma (Hnscc) Involving The Oral Cavity (Excluding Lips), Oropharynx (P16 Negative), Larynx, Or Hypopharynx, Undergone Gross Total Surgical Resection Within 63 Days, Zubrod Performance Status Of 0-1, Adequate Organ Function, No Prior Malignancy Within 3 Years, No Prior Cancer Therapy For Study Cancer, No Previous History Of Organ Transplant Or Immunodeficiency, No Autoimmune Disease
Keywords:
Hnscc, Head And Neck Cancer
For More Information:
Uc Cancer Center
513-584-7658
cancer@uchealth.com